Back HCV Treatment

HCV Treatment

AASLD 2017: Model Shows Hepatitis C Treatment is Cost-Effective in Japan

Treatment of chronic hepatitis C with direct-acting antivirals can lead to substantial savings by preventing the development of liver failure and liver cancer, according to a mathematical modeling study presented at the AASLD Liver Meeting in October in Washington, DC.

alt

Read more:

AASLD 2017: Curing Hepatitis C Leads to Improved Quality of Life

People who were cured of hepatitis C with direct-acting antivirals had sustained improvements in their health-related quality of life, including both physical and mental health measures, according to study results presented at the AASLD Liver Meeting last week in Washington, DC.

alt

Read more:

Merck Discontinues Development of Experimental Hepatitis C Drugs

Late last month Merck announced that it was halting further development of 2 investigational hepatitis C therapies. The first is a 3-drug coformulation containing the HCV protease inhibitor grazoprevir, the NS5A inhibitor ruzasvir, and the HCV polymerase inhibitor uprifosbuvir. The second is a 2-drug combo containing ruzasvir and uprifosbuvir.

alt

Read more:

AASLD 2017: Mavyret Shows High Cure Rates for HCV Genotype 3 and Cirrhosis

Glecaprevir and pibrentasvir, the 2 drugs in the recently approved Mavyret coformulation, demonstrated high sustained response rates for chronic hepatitis C patients with HCV genotype 3 and for people with liver cirrhosis, according to a pair of reports presented at the 2017 AASLD Liver Meeting last week in Washington, DC.

alt

Read more:

Janssen Discontinues Hepatitis C Drug Development Program

Janssen Sciences announced last week that it will stop further development of its experimental hepatitis regimen containing AL-335, odalasvir, and simeprevir, as the market is saturated with effective therapies. It will instead focus on hepatitis B, which is seldom cured with existing antiviral medications.

alt

Read more: